Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Vitespen · HSPPC-96

Vaccine · Immune activation, directed at gp96 heat shock protein · developed by Agenus

Phase 2 Most advanced trial (none active)

AGEN Developer

2 Registered trials

What is Vitespen?

Vitespen is an autologous cancer vaccine derived from a patient's own tumor cells, containing heat shock proteins (gp96) that chaperone tumor-associated peptides. It stimulates dendritic cell maturation and T-cell activation against tumor antigens. It is studied in follicular lymphoma, small lymphocytic lymphoma, and recurrent glioblastoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: HSPPC-96, autologous human tumor-derived HSPPC-96
Drug type: Vaccine
Targets: gp96 heat shock protein (antigen)
Mechanism: Immune activation, directed at gp96 heat shock protein
Pathways: dendritic cell maturation, antigen processing, T-cell activation
Therapy area: Oncology
Developer: Agenus Inc. (AGEN)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2
UNII: H3598Y1TLJ

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT01814813	Phase 2	Recurrent Glioblastoma	Terminated	AGEN
NCT00081809	Phase 2	Lymphoma, Follicular	Completed	AGEN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

GliosarcomaLymphoma, FollicularLymphoma, Small LymphocyticRecurrent Adult Brain TumorRecurrent Glioblastoma

More from Agenus

AGEN1223 Phase 1 AGEN1571 Phase 1 AGEN2017 Phase 1 AGEN2373 Phase 1/2 Balstilimab Phase 2/3 BMS-986442 Phase 1 Botensilimab Phase 2/3 QS21 Phase 2 Zalifrelimab Phase 1/2

Sources

NCI Thesaurus

Updated Oct 3, 2026. Something wrong or missing? Report it on the AGEN page.

Follow AGEN, the company behind Vitespen

See AGEN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AGEN catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z